Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC

Results

Naziv:	Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Autori :	Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 22)
Godina:	2020
Publikacija:	NEW ENGLAND JOURNAL OF MEDICINE
ISSN:	0028-4793 New England Journal of Medicine Pretraži identifikator
Tip rezultata:	Naučni članak
Kolacija:	vol. 383 br. 14 str. 1328-1339
DOI:	10.1056/NEJMoa1917346
WoS-ID:	000575616600009
Scopus-ID:	2-s2.0-85092392792
URI:	https://enauka.gov.rs/handle/123456789/830006
Projekat:	Roche HoldingGenentech IMpower110 ClinicalTrials.gov number [NCT02409342]
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+

1,447
SCOPUS^TM

500
OpenCitations

1,315
WEB OF SCIENCE^TM

Altmetric

Dimensions

Unpaywall